

1 **The clinical characteristics of COVID-19: a retrospective analysis of 104 patients from the**
2 **outbreak on board the Diamond Princess cruise ship in Japan**

3
4 Sakiko Tabata, M.D.^{1†}, Kazuo Imai, M.D.^{1,2*†}, Shuichi Kawano, M.D.^{1,4}, Mayu Ikeda, M.D.¹,
5 Tatsuya Kodama, M.D.¹, Kazuyasu Miyoshi, M.D.¹, Hirofumi Obinata, M.D.^{1,3}, Satoshi Mimura,
6 M.D.¹, Tsutomu Koderu, M.D.¹, Manabu Kitagaki, M.D.¹, Michiya Sato, M.D.¹, Satoshi Suzuki,
7 M.D.¹, Toshimitsu Ito, M.D.¹, Yasuhide Uwabe, M.D.¹, Kaku Tamura, M.D.¹

8
9
10 1 Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan

11 2 Department of Infectious Disease and Infection Control, Saitama Medical University, 38 Moro,
12 Hongo, Iruma-gun, Saitama, Japan

13 3 Department of Emergency and Critical Care Medicine, Nippon Medical School, 1-1-5, Sendagi,
14 Bunkyo-ku, Tokyo, Japan

15 4 Japan Ground Self-Defense Force Medical Service School, 24-2-1, Ikejiri, Setagaya-ku, Tokyo,
16 Japan

17
18 * Corresponding author

19 †Both authors contributed equally

20
21 **Corresponding author**

22 Kazuo Imai, M.D.

23 Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan

24 Department of Infectious Disease and Infection Control, Saitama Medical University, 38 Moro,
25 Hongo, Iruma-gun, Saitama, Japan

26 E-mail: k_imai@saitama-med.ac.jp

27 Tel: 03-3411-0151 or 049-276-111

28 **Abstract**

29 **Background:** The ongoing outbreak of the coronavirus disease 2019 (COVID-19) is a global threat.
30 Identification of markers for symptom onset and disease progression is a pressing issue. We
31 compared the clinical features on admission among patients who were diagnosed with asymptomatic,
32 mild, and severe COVID-19 at the end of observation.

33 **Methods:** This retrospective, single-center study included 104 patients with laboratory-confirmed
34 COVID-19 from the mass infection on the Diamond Princess cruise ship from February 11 to
35 February 25, 2020. Clinical records, laboratory data, and radiological findings were analyzed.
36 Clinical outcomes were followed up until February 26, 2020. Clinical features on admission were
37 compared among those with different disease severity at the end of observation. Univariate analysis
38 identified factors associated with symptom onset and disease progression.

39 **Findings:** The median age was 68 years, and 54 patients were male. Briefly, 43, 41, and 20 patients
40 on admission and 33, 43, and 28 patients at the end of observation had asymptomatic, mild, and
41 severe COVID-19, respectively. Serum lactate hydrogenase levels were significantly higher in 10
42 patients who were asymptomatic on admission but developed symptomatic COVID-19 compared
43 with 33 patients who remained asymptomatic throughout the observation period. Older age,
44 consolidation on chest computed tomography, and lymphopenia on admission were more frequent in
45 patients with severe COVID-19 than those with mild COVID-19 at the end of observation.

46 **Interpretation:** Lactate dehydrogenase level is a potential predictor of symptom onset in COVID-19.
47 Older age, consolidation on chest CT images, and lymphopenia might be risk factors for disease
48 progression of COVID-19 and contribute to the clinical management.

49 **Funding:** Not applicable.

50 **Research in context**

51 **Evidence before this study**

52 We searched the PubMed database from its inception until March 1, 2020, for articles published in
53 English using the keywords “novel coronavirus,” “2019 novel coronavirus,” “2019-nCoV,” “Severe
54 acute respiratory syndrome coronavirus 2,” “SARS-CoV2,” “COVID-19,” “mass infection,” “herd
55 infection,” “cruise ship,” “Diamond Princess,” “asymptomatic,” and “subclinical.” There were no
56 published clinical studies featuring COVID-19 as a result of mass infection on board a cruise ship.
57 We found published articles entitled “Characteristics of COVID-19 infection in Beijing” and
58 “Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive
59 study,” which compared patients with asymptomatic, mild, and severe COVID-19. However, none of
60 the studies described potential markers for symptom onset or disease progression in patients with
61 COVID-19.

62 **Added value of this study**

63 We present the differences in clinical characteristics of 104 patients with laboratory-confirmed
64 COVID-19 as a result of mass infection on the Diamond Princess cruise ship who were treated at
65 Self-Defense Forces Central Hospital, Japan from February 11 to February 25, 2020. On admission,
66 43, 41, and 20 patients had asymptomatic, mild, and severe COVID-19, respectively, whereas 33, 43,
67 and 28 patients were determined to have asymptomatic, mild, and severe COVID-19, respectively, at
68 the end of observation. During the observation period, 10 of the 43 (23.3%) asymptomatic patients
69 on admission developed symptoms of COVID-19. Conversely, eight of the 84 (9.5%) patients with
70 asymptomatic and mild COVID-19 on admission developed severe disease during the observation
71 period. The serum lactate dehydrogenase (LDH) levels were significantly higher in 10 patients who
72 were initially asymptomatic on admission to the hospital and developed symptomatic COVID-19
73 during the observation period compared with 33 patients who remained asymptomatic throughout the
74 observation period. The prevalence rates of consolidation on chest computed tomography (CT)
75 images and lymphopenia were significantly higher in eight patients who developed severe
76 COVID-19 during the observation period compared with the 76 patients with asymptomatic or mild
77 disease at the end of the observation. Older age, consolidation on chest CT, and lymphopenia on
78 admission were more frequent in patients with severe COVID-19 (n = 28) than those with mild
79 COVID-19 (n = 43) at the end of observation. LDH level might be marker for symptom onset in
80 patients with COVID-19, whereas older age, consolidation on chest CT imaging, and lymphopenia
81 are potential risk factors for disease progression. The current report findings will contribute to the
82 improvement of clinical management in patients with COVID-19.

83 **Implications of all the available evidence**

84 Serum LDH level is a potential predictor of symptom onset of COVID-19, whereas older age,
85 consolidation on chest CT imaging, and lymphopenia have potential utility as markers for disease
86 progression.

87

88 **Introduction**

89 The coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute
90 respiratory syndrome coronavirus 2 (SARS-CoV2). The first case was reported in Wuhan, China, in
91 December 2019,¹ and the ongoing outbreak has been declared as a pandemic by the World Health
92 Organization. Since specific treatment for COVID-19 is unknown, identification of patients at high
93 risk for severe illness is critical to prepare and provide sufficient supportive therapy. Additionally, an
94 explosive increase in case numbers has led to the collapse of healthcare systems. Therefore, triage of
95 patients and their transportation to proper facilities are necessary. Although our knowledge of the
96 clinical characteristics of COVID-19 and the pathogenicity of SARS-CoV2 are increasing, detailed
97 clinical characteristics of the disease remain unknown; most of the published studies to date focus on
98 patients with severe COVID-19.²⁻⁵ In Japan, a large number of infections occurred among the
99 passengers and crew members on board the Diamond Princess cruise ship in February 2020. By
100 March 1, 2020, there were approximately 700 patients with laboratory-confirmed SARS-CoV2
101 infection.^{6,7} Approximately 3700 passengers and crew members on the cruise ship were tested for
102 SARS-CoV2 by reverse transcription (RT)-polymerase chain reaction (PCR), and all symptomatic
103 and asymptomatic cases were referred to medical institutions designated for infectious diseases in
104 accordance with the Infectious Diseases Control Law of Japan.^{6,7} Approximately 15% of all
105 laboratory-confirmed cases from Diamond Princess were admitted to the Self-Defense Forces
106 Central Hospital in Japan.

107 In clinical settings, identifying patients who are at risk of symptom onset and clinical deterioration is
108 essential. Therefore, understanding the clinical characteristics of patients with COVID-19 of
109 different severity is necessary. To that end, we retrospectively analyzed the detailed clinical
110 characteristics of hospitalized patients with COVID-19 as a result of the Diamond Princess outbreak,
111 including those with asymptomatic, mild, and severe disease presentation, who were treated in the
112 Self-Defense Forces Central Hospital in Japan.

113

114 **Methods**

115 **Study design and patients**

116 We conducted a retrospective review of the medical records of 104 patients with
117 laboratory-confirmed COVID-19 who were admitted to the Self-Defense Forces Central Hospital in
118 Japan between February 11 and February 25, 2020. Approximately 3700 passengers on the cruise
119 ship were examined by quantitative RT-PCR or nested RT-PCR for SARS-CoV2 using pharyngeal
120 swabs or sputum specimens at the public health institutes based on the recommendations protocol by
121 the National Institute of Infectious Disease.⁶⁻⁸ This study was reviewed and approved by the Japan
122 Self-Defense Forces Central Hospital (approval number 01-011). Informed consent, both written and
123 oral, was obtained from all enrolled patients.

124 **Data collection**

125 Patient information was retrospectively collected from the hospital medical records and included

126 clinical records, laboratory findings, and chest CT images. All data were collected and reviewed by
127 two study investigators (ST and KI).

128 **Definitions**

129 The geographical regions were classified according to the standard country or area codes for
130 statistical use (M49) by the United Nations Statistics Division
131 (<https://unstats.un.org/unsd/methodology/m49/>). Asymptomatic cases were defined as patients with
132 no history of clinical signs and symptoms. Severe symptomatic cases were defined as patients
133 showing clinical symptoms of pneumonia (dyspnea, tachypnea, peripheral capillary oxygen
134 saturation <93%, and need for oxygen therapy).⁹ Patients with other symptoms were classified as
135 mild cases. The observation period was defined as the time interval between the date of admission
136 and the date of discharge or February 26, 2020.

137 **Statistical analysis**

138 Continuous variables were expressed as means with standard deviation or medians with interquartile
139 range (IQR) and compared using Student's *t* test and Wilcoxon rank-sum test for parametric and
140 nonparametric data, respectively. Categorical variables were expressed as numbers (%) and
141 compared by the χ^2 or Fisher's exact test. A two-sided *p* value of less than 0.05 was considered to be
142 statistically significant. All statistical analyses were calculated using Stata13 (Stata Corp, College
143 Station, TX, USA).

144 **Role of the funding source**

145 There was no funding source for this study. The corresponding author had full access to all
146 study-related data and had final responsibility for the decision to submit the study for publication.

147

148 **Results**

149 During the observation period, a total of 107 patients on board the Diamond Princess cruise ship with
150 laboratory-confirmed COVID-19 were hospitalized in the Self-Defense Forces Central Hospital in
151 Japan. Three patients were excluded from the study because of withdrawal of consent to join the
152 study. Therefore, the remaining 104 patients were included in the final analysis. The patients' clinical
153 history, physical examination, and chest CT findings were evaluated on the day of admission, and all
154 blood tests were completed within the first 2 days following admission. The characteristics of 104
155 patients are presented in Table 1. Briefly, the patient age ranged from 25 to 93 years (median, 68
156 years; IQR, 46.75–75 years), and 54 (51.9%) patients were male. Most of the patients were from
157 Eastern Asia, with Japanese and Chinese ethnicities as the majority. The range of observation period
158 was 3–15 days (median, 10 days; IQR, 7–10 days). Fifty-two (50.0%) patients had comorbidities.
159 Based on their presentation on the day of admission, 43 patients (41.4%) who did not display any
160 symptoms were classified as asymptomatic, whereas 41 (39.4%) and 20 (19.2%) patients were
161 classified to have mild and severe COVID-19, respectively.

162

163 The clinical findings of the patients who were symptomatic on the day of admission and at the end of
164 observation period are shown in Table 2. At the end of the observation, there were 33 (31.7%), 43
165 (41.3%), and 28 (26.9%) patients with confirmed asymptomatic, mild, and severe COVID-19,
166 respectively. The most common clinical signs and symptoms on admission among the 71
167 symptomatic patients at the end of the observation were fever (42.3%) and cough (40.8%). Of the 43
168 patients who were asymptomatic on admission, 10 (23.3%) patients developed symptomatic
169 COVID-19 during the observation period, including three (7.0%) patients who developed severe
170 COVID-19 and required supplemental oxygen therapy. Conversely, five of the 41 (12.2%) patients
171 with mild disease on admission developed severe COVID-19 and required supplemental oxygen
172 therapy. Therefore, eight of the 84 (9.5%) patients with asymptomatic or mild presentation on
173 admission developed severe COVID-19 during the observation period. Additionally, of the 71
174 patients who were symptomatic at the end of the observation, 14 (13.5%) and one (1.4%) patient
175 required oxygen therapy and mechanical ventilation, respectively, whereas 10 (14.1%) and five
176 (7.0%) patients were treated by antibiotics and lopinavir/ritonavir, respectively. There were no
177 reports of complications or death during the observation period.

178

179 The characteristics of 10 patients who developed symptomatic COVID-19 during the observation
180 period among those who were asymptomatic on admission are presented in Table 3. Among these 10
181 patients who developed symptomatic COVID-19, the most frequent symptom was cough ($n = 7$,
182 70.0%). Conversely, 17 of the 33 (51.5%) patients never developed symptoms until the end of the
183 observation period had abnormal lung findings with various patterns on CT images (Table 3 and
184 Figure 1). By univariate analysis, there were no significant differences in the distribution of age, sex,
185 and comorbidities or the prevalence of abnormal lung findings and CT patterns between the
186 symptomatic and asymptomatic patients. The prevalence of elevated LDH levels above 230 IU/L was
187 significantly higher in patients who were initially asymptomatic but developed symptomatic
188 COVID-19 during the observation period (50.0% vs 12.1%; odds ratio [OR], 7.25; 95% confidence
189 interval [CI], 1.43–36.70; $p = 0.02$).

190

191 In the group of eight patients who developed severe COVID-19 during the observation period, the
192 age range was 42–87 years (median, 70 years; IQR, 70–77 years), and five (62.5%) patients were
193 male. The period from symptom onset to the reclassification of disease presentation as severe
194 COVID-19 ranged from 1 to 5 days (median, 4 days; IQR, 2.5–5 days). Additionally, all eight
195 patients (100.0%) developed radiographical abnormalities on CT prior to the emergence of
196 symptoms of typical pneumonia including tachypnea, dyspnea, and hypoxemia (Figure 2).
197 Furthermore, among these patients who developed severe COVID-19 during the observation period,
198 4 (50.0%) and 3 (37.5%) patients lacked the symptoms of cough and fever, respectively. We also
199 compared these eight patients who developed severe COVID-19 with 76 patients who remained
200 asymptomatic or had mild COVID-19 at the end of the observation period. By univariate analysis, no

201 significant differences were observed in the distribution of age, sex, and comorbidities between the
202 two groups. The prevalence rates of consolidation (75.0% vs 19.7%; OR, 12.20; 95%CI, 2.23–66.59;
203 $p = 0.04$) and lymphopenia (62.5% vs 25.0%; OR, 5.00; 95%CI, 1.10–22.92; $p = 0.04$) on the day of
204 admission were significantly higher in patients who developed severe COVID-19 during the
205 observation period than in those who were asymptomatic or had mild disease at the end of the
206 observation period.

207

208 Finally, we performed analyses to identify differences in the clinical characteristics between patients
209 with mild and severe COVID-19 at the end of the observation period (Table 4). By univariate
210 analysis, age was significantly higher in the severe COVID-19 group than in the mild COVID-19
211 group (median, 72.5 years; IQR, 55.25–76.5 years vs median, 60 years; IQR, 40.0–71.0 years;
212 $p = 0.03$). There were no significant differences in the distribution of sex, comorbidities, clinical
213 signs, and symptoms between the two groups. However, there was a significant difference in the
214 prevalence of consolidation as a CT pattern between the severe and mild cases (46.4% vs 20.9%; OR,
215 3.27; 95%CI, 1.15–9.30; $p = 0.03$). Among the blood tests, the rate of lymphopenia was higher in
216 patients with severe COVID-19 than in those with mild COVID-19 at the end of the observation
217 period (57.1% vs 23.3%; OR, 4.40; 95% CI; 1.57–12.32; $p = 0.005$).

218

219 **Discussion**

220 The present retrospective, single-center study provides a summary of the clinical features of patients
221 who developed COVID-19 of varying severity as a result of mass infection on board a cruise ship.
222 The LDH levels were significantly higher in 10 patients who were initially asymptomatic on
223 admission to the hospital and developed symptomatic COVID-19 during the observation period than
224 in 33 patients who remained asymptomatic throughout the observation period. Older age,
225 consolidation on chest CT images, and lymphopenia at the time of admission were significantly more
226 frequent among 28 patients with severe COVID-19 than among 43 patients with mild COVID-19 at
227 the end of the observation period. Overall, these findings suggest that serum LDH level might be a
228 marker of symptom onset and that older age, consolidation on chest CT images, and lymphopenia are
229 potential risk factors for disease progression in patients with COVID-19.

230

231 The predictors of symptom onset and risk factors for disease progression in COVID-19 remain
232 partially unclear because patients who are asymptomatic or are otherwise exhibiting mild symptoms
233 do not necessarily visit a hospital. During the COVID-19 outbreak on the Diamond Princess cruise
234 ship, approximately 3700 individuals on board were tested for SARS-CoV2 by RT-PCR, and all
235 laboratory-confirmed patients were referred to the hospitals. This unique situation allowed us to
236 observe the clinical course of asymptomatic patients as well as those with mild and severe symptoms,
237 which has not been reported to date.²⁻⁵

238

239 Based on the previously published findings of COVID-19 in China, old age, male sex, and presence
240 of comorbidities are considered as potential risk factors for disease progression and poor prognosis.
241 ^{1,10} Zhou *et al.* indicated that older age, high sequential organ failure assessment score, and elevated
242 d-dimer level were potential risk factors for death in patients with COVID-19. ¹¹ Qin *et al.* reported
243 that lymphopenia and higher neutrophil–lymphocyte ratio were frequently observed in patients with
244 severe COVID-19 compared with those with mild disease. The present study findings support those
245 of previous reports suggesting older age and lymphopenia as potential risk factors for disease
246 progression in COVID-19. Lymphopenia, a common feature of symptomatic COVID-19, ^{12,13} can be
247 a direct consequence of SARS-CoV2 or might be mediated by cytokines. Qin *et al.* also suggested
248 that SARS-CoV2 infection might affect T lymphocytes and dysregulate the immune system,
249 consequently leading to secondary bacterial infections. ¹⁴ In the present study, we observed
250 lymphopenia in 27.3% of the patients who were asymptomatic at the end of observation period,
251 which suggests the development of immune system dysregulation as a direct consequence of
252 SARS-CoV2 infection in asymptomatic cases. However, the role lymphopenia in asymptomatic
253 patients remains unclear. Further cohort studies are warranted to determine the effect of lymphopenia
254 caused by SARS-CoV2 infection in the presence of secondary bacterial infection.

255

256 In the present study, the prevalence of consolidation detected by chest CT was significantly higher in
257 severe cases than in mild cases. Consolidation was also frequently detected in patients who
258 developed severe COVID-19 during the observation period. Pan *et al.* and Shi *et al.* reported that
259 abnormal lung findings varied from ground glass opacities (GGOs) to consolidation during the
260 course of COVID-19 and that the appearance of consolidation was more frequent within 1–3 weeks
261 after the symptom onset. ^{15,16} Previous studies found that 55% of patients with COVID-19 developed
262 dyspnea in a median of 8 days (IQR, 5.0–13.0 days) after symptom onset; ¹ thus, the development of
263 consolidation on CT is associated with disease deterioration. Generally, consolidation is easily
264 detectable by chest X-ray, which therefore might be useful for the evaluation of risk for disease
265 progression in patients with COVID-19 in settings with limited resources.

266

267 Additionally, CT imaging revealed a high prevalence of lung abnormalities in patients with
268 COVID-19. The various patterns of abnormal lung findings were observed in asymptomatic cases
269 (51.5%) as well as in symptomatic cases (69.0%) at the end of the observation period. In their report
270 focusing on CT imaging findings of COVID-19, Shi *et al.* also noted the presence of abnormal lung
271 findings in asymptomatic patients. ¹⁶ Bai *et al.* investigated the common radiological characteristics
272 of COVID-19 pneumonia and reported that chest CT had a diagnostic sensitivity of 73%–93% and a
273 specificity of 93%–100% in distinguishing COVID-19 from viral pneumonia. ¹⁷ Therefore, chest CT
274 imaging might also be useful diagnostic tool for the asymptomatic and symptomatic patients with
275 COVID-19. In the present study, all eight patients who developed severe COVID-19 during the
276 observation period presented with CT abnormalities, in advance of the appearance of typical

277 pneumonia symptoms such as dyspnea, tachypnea, and hypoxemia. Of these eight patients, four and
278 three patients lacked the symptoms of cough and fever, respectively. These findings highlight that
279 COVID-19 pneumonia silently progresses without any remarkable symptoms. Conversely, the
280 majority of asymptomatic patients with radiological abnormalities on CT imaging did not develop
281 severe pneumonia. The differences observed in the clinical outcomes might be associated with
282 patient background characteristics as well as the genetic and pathogenic diversity of SARS-CoV2.
283 Understanding CT abnormalities relevance to the duration of virus shedding and the incidence of
284 secondary bacterial pneumonia is important to improve the clinical management of COVID-19.
285 Further investigation is necessary to clarify the clinical impact of CT findings in patients with
286 asymptomatic or mild COVID-19.

287

288 Interestingly, there was a significant difference in the rate of patients with elevated LDH levels
289 between those who developed symptomatic COVID-19 during the observation period and those who
290 remained asymptomatic throughout the observation period, although there was no significant
291 difference in the prevalence of lymphopenia between the two groups. Elevated serum LDH levels are
292 associated with lung tissue damage,¹⁸ and serum LDH is considered as a marker for disease activity
293 and progression in pneumonia due to various etiologies.^{19,20} Given that abnormal lung findings are
294 frequently observed in patients with asymptomatic COVID-19, these findings implicate that an
295 elevated LDH level might also reflect lung tissue damage by COVID-19 and might be considered as
296 a predictor for symptom onset in COVID-19. Patient assessment with determination of serum LDH
297 levels and chest CT imaging might facilitate the successful dedication of medical resources to
298 patients who are at higher risk for disease progression in the setting of mass infections as well as in
299 normal clinical settings.

300

301 The major limitations of the present study were selection bias and low number of patients. We
302 enrolled an ideal, homogeneous cluster of relatively healthy individuals who could remain on board a
303 cruise ship for a relatively long term. Therefore, the patient population was not an exact
304 representation of normal clinical settings. Triage on the Diamond Princess cruise ship before
305 emergency transportation has also introduced a selection bias with an atypically large number of
306 patients. The Self-Defense Forces Central Hospital in Tokyo is close to the Yokohama port where the
307 cruise ship was docked, and the symptomatic cases were referred to the study hospital. However, the
308 critical cases were preferentially referred to neighboring hospitals in Yokohama. Likewise, several
309 clinical signs and symptoms, which have occurred and disappeared before the patients were referred
310 to our hospital, may be included or excluded from this study. In addition, laboratory tests and CT
311 images were obtained once in majority of the patients, and the present study was not able to
312 determine changes in lymphocyte count and radiological findings over the course of observation.
313 Therefore, multicenter, multi-national cohort studies should be conducted to determine predictive
314 markers for symptom onset and risk factors for diseases progression.

315

316 **Conclusion**

317 The present study highlights the clinical features of patients who developed COVID-19 as a result of
318 mass infection on board the Diamond Princess cruise ship. Our analyses reveal serum LDH level as a
319 potential predictor of symptom onset in COVID-19. Age, consolidation on chest CT images, and
320 lymphopenia might be risk factors for disease progression. These findings contribute to a better
321 understanding of the clinical course and access points to improve disease management in patients
322 with COVID-19. Additional cohort studies are warranted to determine predictors for symptom onset
323 and risk factors for disease progression.

324

325 **Declaration of interests**

326 The authors declare that they have no conflicts of interests.

327

328 **Role of the funding source**

329 This research did not receive any specific grant from funding agencies in the public, commercial, or
330 nonprofit sectors. The corresponding author had full access to all study-related data and had final
331 responsibility for the decision to submit the study for publication.

332

333 **Authors' contributions**

334 TI and KT, study conception and design; ST and KI, collecting data and performing data analysis; ST,
335 KI, MI, and KM manuscript drafting and editing; TaK, HO, SK, TsK, MK and SM, manuscript
336 revision; MS, SS and UY, study supervision. All authors have read and approved the final
337 manuscript.

338

339 **Acknowledgments**

340 We thank everyone involved in the COVID-19 management and treatment team from the
341 Self-Defense Forces Central Hospital in Japan and members who were assembled from other
342 institutes of Japan Self-Defense Forces. Particularly, we thank Dr. Koji Kameda, Dr. Takayuki
343 Yamamoto, Dr. Daishi Higashiyama, Dr. Yoshitaka Imoto, Dr. Masataka Miyama, Dr. Tsukasa
344 Mizuno, Dr. Kento Kato, Dr. Mamoru Honda, Dr. Shoji Takeda, and Dr. Masumi Ogawa, Dr. Shingo
345 Tanaka, Dr. Hisashi Sasaki, Dr. Mitsuki Yamaga, Dr. Shinichiro Ota and Dr. Hiroaki Taniguchi for
346 supporting the data collection, and Dr. Akira Fujikawa and Dr. Shohei Inui for the interpretation of
347 chest CT images. We also thank Mr. Shingo Tamaki (School of Tropical Medicine and Global Health,
348 Nagasaki University, Japan) for the supporting statistical analysis, Colonel. Kazuhiro Nakaya
349 (Medical Department, Ground Staff Office, Ministry of Defense) for the scientific advice, and Enago
350 (www.enago.jp) for the English language review.

351 **References**

- 352 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
353 coronavirus in Wuhan, China. *The Lancet* 2020; **395**(10223): 497-506.
- 354 2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by
355 SARS-CoV-2 in Wuhan, China. *Allergy* 2020. doi: 10.1111/all.14238.
- 356 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
357 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020;
358 **395**(10223): 507-13.
- 359 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
360 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**(11):1061-1069.
- 361 5. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and
362 Critical COVID-19 Pneumonia. *Investigative Radiology* 2020. doi:
363 10.1097/RLI.0000000000000672.
- 364 6. Kakimoto K, Kamiya H, Yamagishi T, Matsui T, Suzuki M, Wakita T. Initial Investigation of
365 Transmission of COVID-19 Among Crew Members During Quarantine of a Cruise Ship —
366 Yokohama, Japan, February 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:312-313. DOI:
367 <http://dx.doi.org/10.15585/mmwr.mm6911e2>
- 368 7. National Institute of Infectious Diseases. Field briefing: Diamond Princess COVID-19 cases.
369 Tokyo, Japan: National Institute of Infectious Diseases; 2020.
370 <https://www.niid.go.jp/niid/en/2019-ncov-e/9407-covid-dp-fe-01.html> [Latest
371 26/Mar/2020]
- 372 8. Nao N, Shirato K, Katano H, et al. Detection of second case of 2019-nCoV infection in
373 Japan. National Institute of Infectious Diseases.
374 [.https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf](https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf) [Latest
375 accessed 26/Mar/2020]
- 376 9. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for
377 2019 novel coronavirus disease in fever clinics. *The Lancet Respiratory Medicine* 2020. doi:
378 [https://doi.org/10.1016/S2213-2600\(20\)30071-0](https://doi.org/10.1016/S2213-2600(20)30071-0)
- 379 10. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus
380 (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious*
381 *Diseases* 2020. doi: <https://doi.org/10.1016/j.ijid.2020.03.017>.
- 382 11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
383 with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet* 2020. doi:
384 [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
- 385 12. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
386 China. *New England Journal of Medicine* 2020. doi: 10.1056/NEJMoa2002032.
- 387 13. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission
388 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

389 *The Lancet* 2020. doi: [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3).

390 14. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19
391 in Wuhan, China. *Clinical Infectious Diseases* 2020. doi: <https://doi.org/10.1093/cid/ciaa248>.

392 15. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery
393 From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* 2020: 200370. doi:
394 <https://doi.org/10.1148/radiol.2020200370>.

395 16. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19
396 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases*. doi:
397 [https://doi.org/10.1016/S1473-3099\(20\)30086-4](https://doi.org/10.1016/S1473-3099(20)30086-4).

398 17. Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19
399 from viral pneumonia on chest CT. *Radiology*; **0**(0): 200823. doi:
400 <https://doi.org/10.1148/radiol.2020200823>.

401 18. Drent M, Cobben N, Henderson R, Wouters E, van Dieijen-Visser M. Usefulness of lactate
402 dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *European*
403 *Respiratory Journal* 1996; **9**(8): 1736-42.

404 19. Quist J, Hill AR. Serum Lactate Dehydrogenase (LDH) in Pneumocystis carinii Pneumonia,
405 Tuberculosis, and Bacterial Pneumonia. *Chest* 1995; **108**(2): 415-8.

406 20. Lu A, Wang C, Zhang X, Wang L, Qian L. Lactate Dehydrogenase as a Biomarker for
407 Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. *Respiratory care* 2015;
408 **60**(10): 1469-75.

409

410

411 **Figure Legends**

412 Figure 1. Computed tomography (CT) patterns of abnormal lung findings among asymptomatic
413 patients with the 2019 novel coronavirus disease (COVID-19). (A–D) A 73 year-old female patient.
414 Patchy non-segmental GGOs are observed adjacent to the parietal pleura in the right upper lobe (A
415 and B) and in both lower lobes (C and D). (E) A 70 year-old female patient. GGO with interlobular
416 septal thickening (crazy-paving appearance) adjacent to the parietal pleura in both lower lobes. (F) A
417 76 year-old male. CT image shows GGO with consolidation, bronchial wall thickening, and
418 bronchiectasis in left lower lobe.

419

420 Figure 2. Progression of CT findings in a 75 year-old male patient with COVID-19. The patient was
421 asymptomatic on the day of admission. On the fourth day of admission, he developed tachypnea and
422 hypoxemia and was administered oxygen therapy. (A–C) Chest CT images on the day of admission
423 show multifocal GGO adjacent to the parietal pleura in multiple lobes with emphysematous changes.
424 (D–F) Follow-up chest CT images on the tenth day of admission show an increase in the extent of
425 GGO with crazy-paving appearance.

426 **Table 1. Baseline characteristics of patients with COVID-19 on the Diamond Princess cruise**
 427 **ship**

Total number of patients (n = 104)	
Characteristics	
Age	68 [46.75–75]
Sex (male)	54 (51.9%)
Observation period (days)	10 [7–10]
Time from onset to admission (days)	5 [2–7]
Nationality	
Eastern Asia	55 (52.9%)
Southeast Asia	21 (20.2%)
Europe	4 (3.8%)
Northern America	14 (13.5%)
Oceania	4 (3.8%)
Others	6 (5.8%)
Smoking	
Yes	18 (17.3%)
Comorbid condition	
Total	52 (50.0%)
Cardiovascular disease	31 (29.8%)
Endocrine disorder	9 (8.7%)
Diabetes mellitus	7 (6.7%)
Respiratory disorder	7 (6.7%)
Malignancy	4 (3.8%)
Severity on admission	
Asymptomatic	43 (41.4%)
Mild	41 (39.4%)
Severe	20 (19.2%)

428 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

Table 2. Clinical findings and disease severity of 71 patients with symptomatic COVID-19

	Number (%)	
	On admission	At the end of observation
Signs and symptoms		
Fever	30 (42.3%)	36 (50.7%)
Cough	29 (40.8%)	43 (60.6%)
Malaise	12 (16.9%)	22 (31.0%)
Headache	10 (14.1%)	18 (25.4%)
Sore throat	11 (15.5%)	11 (15.5%)
Runny nose	16 (22.5%)	24 (33.8%)
Diarrhea	8 (11.3%)	10 (14.1%)
Dyspnea	7 (9.9%)	19 (26.8%)
Tachypnea	16 (22.5%)	24 (33.8%)
SpO ₂ < 93%	3 (4.2%)	14 (19.7%)
Treatment		
Acetaminophen	4 (5.6%)	15 (21.1%)
NSAIDs	-	1 (1.4%)
Antibiotics	-	10 (14.1%)
Lopinavir/ritonavir	-	5 (7.0%)
Oxygen therapy	3 (4.2%)	14 (19.7%)
Mechanical ventilation	-	1 (1.4%)
Severity		
Asymptomatic	10 (14.1%)	-
Mild	41 (57.7%)	43 (60.6%)
Severe	20 (28.2%)	28 (39.4%)

430 Data are presented as n (%).

431 NSAID, non-steroidal anti-inflammatory drug; SpO₂, peripheral capillary oxygen saturation

432 **Table 3. Clinical characteristics of 43 asymptomatic patients on admission**

	Total n = 43	At the end of observation		p value	OR (95% CI)
		Asymptomatic n = 33	Symptomatic n = 10		
Characteristics					
Age	69 [60.5–75]	70 [57–75]	67.5 [66.25–73.5]	0.96	
Sex (male)	19 (44.2%)	15 (45.5%)	4 (40.0%)	1.00	
Smoking					
Yes	7 (16.3%)	5 (15.2%)	2 (20.0%)	0.65	
Comorbid condition					
Total	21 (48.8%)	15 (45.5%)	6 (60.0%)	0.48	
Cardiovascular disease	12 (27.9%)	9 (27.3%)	3 (30.0%)	1.00	
Endocrine disorder	3 (7.0%)	2 (6.1%)	1 (10.0%)	0.56	
Diabetes mellitus	5 (11.6%)	5 (15.2%)	-	0.32	
Respiratory disorder	4 (9.3%)	2 (6.1%)	2 (20.0%)	0.22	
Malignancy	2 (4.7%)	1 (3.0%)	1 (10.0%)	0.42	
Signs and symptoms					
Fever	3 (7.0%)	-	3 (30.0%)	-	
Cough	7 (16.3%)	-	7 (70.0%)	-	
Malaise	2 (4.7%)	-	2 (20.0%)	-	
Headache	2 (4.7%)	-	2 (20.0%)	-	
Sore throat	-	-	-	-	
Runny nose	-	-	-	-	
Diarrhea	1 (2.3%)	-	1 (10.0%)	-	
Dyspnea	3 (7.0%)	-	3 (30.0%)	-	
Tachypnea	3 (7.0%)	-	3 (30.0%)	-	
SpO ₂ < 93%	3 (7.0%)	-	3 (30.0%)	-	
Radiographically findings on admission					
Abnormal lung findings	25 (58.1%)	17 (51.5%)	8 (80.0%)	0.15	
Lateral	13 (30.2%)	10 (30.3%)	3 (30.0%)	-	
Bilateral	12 (27.9%)	7 (21.2%)	5 (50.0%)	0.11	
GGO	15 (34.9%)	11 (33.3%)	4 (40.0%)	0.72	
Multifocal GGO	12 (27.9%)	9 (27.3%)	3 (30.0%)	1.00	
Consolidation	9 (20.9%)	6 (18.2%)	3 (30.0%)	0.41	
Crazy-paving appearance	5 (11.6%)	2 (6.1%)	3 (30.0%)	0.07	

Nodular lesion	3 (7.0%)	2 (6.1%)	1 (10.0%)	0.56	
Laboratory findings on admission					
AST > 38 (IU/L)	4 (9.3%)	3 (9.1%)	1 (10.0%)	1.00	
ALT > 45 (IU/L)	5 (11.6%)	4 (12.1%)	1 (10.0%)	1.00	
LDH > 230 (IU/L)	9 (20.9%)	4 (12.1%)	5 (50.0%)	0.02*	7.25 (1.43–36.70)
CRP > 1.0 (mg/dL)	18 (41.9%)	11 (33.3%)	7 (70.0%)	0.07	
White blood cell count <4000 (/μL)	6 (14.0%)	4 (12.1%)	2 (20.0%)	0.61	
Platelet count <15 (×10 ⁴ /μL)	2 (4.7%)	1 (3.0%)	1 (10.0%)	0.41	
Lymphocyte count <1200 (/μL)	13 (30.2%)	9 (27.3%)	4 (40.0%)	0.46	

433 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

434 Asterisk indicates statistical significance.

435 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground glass opacity; AST, aspartate
436 aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive
437 protein

438 **Table 4. The clinical characteristics of patients with mild and severe COVID-19 at the end of**
 439 **observation**

	Total n = 71	Mild n = 43	Severe n = 28	p value	OR (95% CI)
Characteristics					
Age	67 [44–75]	60 [40–71]	72.5 [55.25–76.5]	0.03*	
Sex (male)	39 (54.9%)	22 (51.2%)	17 (60.7%)	0.47	
Smoking					
Yes	13 (18.3%)	6 (14.0%)	7 (25.0%)	0.35	
Comorbid condition					
Total	37 (52.1%)	19 (44.2%)	18 (64.3%)	0.14	
Cardiovascular disease	22 (31.0%)	11 (25.6%)	11 (39.3%)	0.3	
Endocrine disorder	7 (9.9%)	3 (7.0%)	4 (14.3%)	0.42	
Diabetes mellitus	2 (2.8%)	1 (2.3%)	1 (3.6%)	1.00	
Respiratory disorder	5 (7.0%)	2 (4.7%)	3 (10.7%)	0.38	
Malignancy	3 (4.2%)	2 (4.7%)	1 (3.6%)	1.00	
Acetaminophen on admission					
Yes	4 (5.6%)	4 (9.3%)	-	0.15	
Signs and symptoms on admission					
Fever	30 (42.3%)	19 (44.2%)	11 (39.3%)	0.8	
Cough	29 (40.8%)	16 (37.2%)	13 (46.4%)	0.49	
Malaise	12 (16.9%)	6 (14.0%)	6 (21.4%)	0.52	
Headache	10 (14.1%)	8 (18.6%)	2 (7.1%)	0.3	
Sore throat	11 (15.5%)	7 (16.3%)	4 (14.3%)	1.00	
Runny nose	16 (22.5%)	8 (18.6%)	8 (28.6%)	0.39	
Diarrhea	8 (11.3%)	5 (11.6%)	3 (10.7%)	1.00	
Dyspnea	7 (9.9%)	-	7 (25.0%)	-	
Tachypnea	16 (22.5%)	-	16 (57.1%)	-	
SpO ₂ < 9%	3 (4.2%)	-	3 (10.7%)	-	
Radiographically findings on admission					
Abnormal lung finding	49 (69.0%)	26 (60.5%)	23 (82.1%)	0.07	
Lateral	17 (23.9%)	11 (25.6%)	6 (21.4%)	-	
Bilateral	31 (43.7%)	15 (34.9%)	16 (57.1%)	0.09	
GGO	37 (52.1%)	18 (41.9%)	19 (67.9%)	0.05	
Multifocal GGO	34 (47.9%)	17 (39.5%)	17 (60.7%)	0.09	
Consolidation	22 (31.0%)	9 (20.9%)	13 (46.4%)	0.03*	3.27 (1.15–9.30)

Crazy-paving appearance	19 (26.8%)	8 (18.6%)	11 (39.3%)	0.1	
Nodular lesion	5 (7.0%)	4 (9.3%)	1 (3.6%)	0.64	
Laboratory findings on admission					
AST > 38 (IU/L)	15 (21.1%)	6 (14.0%)	9 (32.1%)	0.08	
ALT > 45 (IU/L)	13 (18.3%)	6 (14.0%)	7 (25.0%)	0.35	
LDH > 230 (IU/L)	23 (32.4%)	13 (30.2%)	10 (35.7%)	0.8	
CRP > 1.0 (mg/dL)	42 (59.2%)	23 (53.5%)	19 (67.9%)	0.32	
White blood cell count <4000 (/μL)	15 (21.1%)	9 (20.9%)	6 (21.4%)	1.00	
Platelet count <15 (×10 ⁴ /μL)	7 (9.9%)	5 (11.6%)	2 (7.1%)	0.7	
Lymphocyte count <1200 (/μL)	26 (36.6%)	10 (23.3%)	16 (57.1%)	0.005*	4.4 (1.57–12.32)

440 Data are presented as n (%), or median [interquartile range], unless otherwise specified.

441 Asterisk indicates statistical significance.

442 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground glass opacity; AST, aspartate
 443 aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive
 444 protein



